| Autor: |
Susana Campos, Ursula Matulonis, Suzanne Berlin, Neil Horowitz, Joyce Liu, Carolyn Krasner, Lee Hang, Corrine Zarwan, William Barry, Tina Colella, Christen Whalen, Melina Shoni, Christine Lundquist, Michael J. Birrer, Richard Penson |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
International journal of clinical oncology. 27(12) |
| ISSN: |
1437-7772 |
| Popis: |
The combination of paclitaxel to platinum remains the backbone of therapy in patients with advanced Mullerian tumors. In patients with newly diagnosed Mullerian tumors, we investigated the progression-free survival benefit of bevacizumab and bevacizumab and erlotinib as consolidation therapy post-induction therapy.Sixty patients were enrolled in a phase II trial of carboplatin, paclitaxel, and bevacizumab (induction therapy). After the completion induction therapy, patients were stratified by response (≥ SD) and then randomized (1:1) to either bevacizumab (A) or bevacizumab and erlotinib (AE.) The primary endpoint was PFS. Secondary endpoints included the response rate of induction and consolidation therapy and toxicity profile of each consolidative arm. Each consolidative arm was compared to the historical control GOG 111.Forty-eight patients advanced to the consolidative phase of the trial. Twelve patients were removed in the induction phase, the majority for toxicity. The most common toxicity (grade ≥ 3) was diarrhea (20%: arm AE; 0%: arm A). One patient in the AE arm had a fatal cardiac arrest deemed unrelated to the study treatment. No gastrointestinal perforations were reported. The median PFS in the AE and A arm was 18.9 months (p 0.0001) and 13.3 months (p: ns), respectively. The overall rate of grade 3/4 toxicities in the AE arm was 72% and in the A arm 30%. Six patients remain free of disease 10 years after enrollment.Combinatorial consolidation therapy with AE was associated with an improved progression-free survival in patients with Mullerian tumors. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink